Pipelines

Pseudomonas aeruginosa is one of the most clinically threatening and drug-resistant pathogens, ranking second among the 12 superbugs most urgently in need of antimicrobials (World Health Organization, 2017). In 2022, more than 420,818 cases of P. aeruginosa infections were detected in Chinese medical institutions, with a 16.6% drug resistance rate to carbapenems (CRPA).

The phage library of P. aeruginosa at CreatiPhage is characterized by high quality, comprehensive information, and broad intra-specie coverage. Therefore, CPD-PA01 is a natural phage cocktail that broadly targets clinically prevalent strains of drug-resistant P. aeruginosa. It is in liquid form and indicated for wound infections. In preclinical studies, it demonstrated broad-spectrum bactericidal activity against P. aeruginosa isolates associated with wound and pulmonary infections, with a favorable animal safety profile. An investigator-initiated phase 1/2 randomized controlled clinical trial conducted in collaboration with partner institutions has now completed patient enrollment.

Acinetobacter baumannii accounts for over 400,000 related deaths annually worldwide, ranking first among 12 superbugs (World Health Organization, 2017). In China, 220,000 cases of Acinetobacter baumannii infections were detected in healthcare facilities in 2020, 53.7% of which were resistant to carbapenem antibiotics (CRAB), with no new antibiotics available. 

CreatiPhage's A. baumannii phage library is of high quality, with comprehensive information and wide strain coverage. The CPD-AB01, a natural phage cocktail covering drug-resistant strains, is currently undergoing preclinical studies. The initial pipeline is indicated for lung infections, with the phage formulation being a liquid administered via inhalation.

The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are the most common, drug-resistant, and difficult-to-treat pathogens worldwide, causing over 3.2 million related deaths annually, ranking at the top of the WHO's list of 12 superbugs in 2017. In China, 2.168 million cases of ESKAPE infections were monitored in healthcare facilities in 2020. For specific pathogens infected patients, CreatiPhage utilizes its established standard cPhageBank high-throughput phage screening technologies, and phage combination system to quickly select the most suitable personalized phage cocktail formula for treatment. 

Currently, CreatiPhage is working with partner medical institutions to advance the clinical research filing of phage therapy as a New Biomedical Technology. The phage dosage form is a liquid, and the initial indications are Acinetobacter baumannii pneumonia and Klebsiella pneumoniae urinary tract infection, using commonly used clinical administration regimens such as nebulized inhalation and bladder instillation..

For the most common, drug-resistant superbugs that are prone to hospital-acquired infections and transmission within human environments such as healthcare facilities, nursing homes, and households, a series of broad-spectrum phage cocktail products targeting clinically prevalent bacterial strains have been developed. This fixed formula product can be dynamically updated based on changes in clinically prevalent strains with product types including environmental improvement agents in liquid, powder, and tablet forms, suitable for healthcare facilities, nursing homes, and home environments with infected or susceptible individuals. 

The PHAGINK™ series' first pipeline is a fixed formula product targeting targeting clinically prevalent ESKAPE antibiotic-resistant strains, applicable for empirical (non-customized environmental spraying to reduce the risk of transmission of the aforementioned bacteria. Follow our WeChat (CreatiPhage), visit our Taobao/ WeChat store (创噬纪霏集噬菌体商城), or contact us for more information.

CreatiPhage provides custom product development and bactericidal services for residential and food-processing environments. Target bacteria and related information are obtained through environmental sampling and assessment, a phage cocktail is rapidly formulated for the target, and designated medical and household foggers are used for environmental misting to specifically target and reduce the load of target bacteria in the environment. For long-term partnerships, bacterial infection and transmission can be monitored through phage lytic-spectrum typing and environmental microbiome sequencing of bacteria detected at different time points and sampling sites, enabling timely intervention and the identification and improvement of weak links in infection control.